James E. Carley, MD   OFFICE LOCATION Cardiology Research Associates (1985-Present) Cardiology Physicians, PA (1976-Present) 873 Sterthaus Ave, Suite 302 Ormond Beach, Florida 32174   TELEPHONE: Office: 386-671-0691 Fax: 386-671-0694   Support Staff: C. Janell Lucero, R.N.

EDUCATION

 

MEDICAL LICENSE:

Florida (ME0027632)

 

 

CERTIFICATION

 

PROFESSIONAL SOCIETIES

 

Fellow-American College of Cardiology
Volusia County Medical Society
Fellow-American Society of Geriatric Cardiology

 

 

HOSPITAL AFFILIATIONS

 

 

OFFICES HELD

 

PUBLICATIONS

 

1) Carley, J.E., Wong, B.Y.S, Pugh, D.M. and Dunn, M.I. Clinical Significance of the V Wave in the Main Pulmonary Artery. American Journal of Cardiology. 39-982-985; 1977.

2) Meyer, B., Bogart, D.B., Carley, J.E., Wong, B.Y.S. and Dunn, M.I. Pulmonary Arterial Pulsus Alternans Secondary to Primary Pulmonary Hypertension. Chest.

3) Carley, J.E. and Dunn, M.I. Syncope. Cardiac Emergencies. 6:95-118; 1977.

4) Greenberger, N.J., Carley, J.E., Schenker, S., Bettinger, I., Stames, C. and Beyes, P. Effect of Animal and Vegetable Protein Diets in Chronic Hepatic Encephalopathy. American Journal of Digestive Disease. 22(10):845-855;1977.

 

RESEARCH ACTIVITY

 

CONGESTIVE HEART FAILURE

Sub-Investigator in (3) clinical trials for SmithKline and French Laboratories: Long and Short-term evaluation protocols for congestive heart failure.

Sub-Investigator for Ciba-Geigy in a clinical trial evaluating an investigational vasodilator in congestive heart failure.

Principal Investigator for Hoechst-Roussel Pharmaceuticals in a clinical trial evaluating Ramipril in the treatment of congestive heart failure.

Sub-Investigator for G.H. Besselaar Associates in (3) clinical trials evaluating Benazepril in the treatment of congestive heart failure.

Sub-Investigator for Bristol-Myer Squibb in (2) clinical trials utilizing Fosinopril and Zofinopril in the treatment of congestive heart failure.

Principal Investigator for Pfizer in a hemodynamic clinical trial of Amlodipine for congestive heart failure.

Principal Investigator for Merck heart failure trial comparing Captopril and Losartan. (ELITE)

Sub-Investigator for Otsuka America Pharmaceuticals in the treatment of NYHA Class III-IV congestive heart failure. (VEST)

Principal Investigator for Pfizer Pharmaceuticals in the treatment of non-ischemic NYHA Class III-IV congestive heart failure. (PRAISE-2)

Sub-Investigator for Ciba-Geigy in a clinical trial for morbidity and mortality in congestive heart failure NYHA Class II-IV. (VALHEFT)

Principal Investigator for Scios in (2) clinical trials utilizing intravenous Natrecor in the treatment of decompensated congestive heart failure.

Sub-Investigator for Bristol-Myers Squibb in the treatment of congestive heart failure. (IMPRESS)

Sub-Investigator for SmithKline Beecham in a mortality clinical trial of severe congestive heart failure. (COPERNICUS)

Sub-Investigator for Eli Lilly, in a morbidity and mortality clinical trail for congestive heart failure. (MOXCON)

Sub-Investigator for Bristol-Myers Squibb in a clinical trial evaluating patients with chronic heart failure NYHA Class II-IV. (OVERTURE)

Sub-Investigator for SmithKline Beecham in a clinical trial for the treatment of stable NYHA Class II-III congestive heart failure. (ENCOR)

Sub-Investigator for Searle Pharmaceutical in a clinical trial for the treatment of heart failure following an acute myocardial infarction. (EPHESUS)

Sub-Investigator for Centocor Phase II clinical trial for the treatment of heart failure Class III or IV evaluating the effects of Infliximab (Remicade) – (ATTACH)

Sub-Investigator for St. Jude Medical in a heart failure Class III or IV ventricular resynchronization therapy randomized trial. (VECTOR)

Principal Investigator for Myogen in an advanced heart failure Class III or IV placebo-controlled phase III clinical trial. (ESSENTIAL)

Principal Investigator for Otsuka Maryland Research Institute Incorporated, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evalaute the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure. (EVEREST)

 

LEFT VENTRICULAR DYSFUNCTION

Sub-Investigator for Bristol-Myers Squibb in a mortality clinical trial for patients with ASHD and left ventricular dysfunction. (SWORD)

Sub-Investigator for Schering-Plough in a clinical trial of Nitro-Dur in post AMI patients.

Principal Investigator for Novartis in a clinical trial for treatment of high-risk patients after myocardial infarction. (VALIANT)

 

ACUTE MYOCARDIAL INFARCTION

Principal Investigator in a clinical trial for intravenous Metoprolol in the treatment of AMI.

Sub-Investigator for SmithKline and French Laboratories in a clinical trial of Eminase as thrombolytic treatment of AMI.

Sub-Investigator for Bristol-Myers Squibb in a clinical trial of throbolytic treatment in AMI. (IN-TIME)

Sub-Investigator for Genentech, Incorporated and Boehringer Ingelheim, Ltd. in the treatment of AMI with thrombolytic treatment. (ASSENT I)

Sub-Investigator for Bristol-Myers Squibb in the thrombolytic treatment of patients with AMI. (IN-TIME II)

Principal Investigator for Centocor in a clinical trial for the treatment of AMI. (GUSTO V)

 

ACUTE CORONARY SYNDROME

Principal Investigator for Hoechst Marion Roussell in the treatment of patients at risk of myocardial necrosis due to acute coronary syndrome. (GUARDIAN)

Principal Investigator for Searle in the treatment of patients with unstable coronary syndromes. (OPUS-TIMI 16)

Sub-Investigator for Rhone-Poulenc Rore Pharmaceutical in the treatment of unstable angina and non-Q-wave MI. (ESSENCE)

Sub-Investigator for Roche Pharmaceuticals in a clinical trial for treatment of patients post acute coronary syndrome. (2nd SYMPHONY)

Principal Investigator for Bristol Myers Squibb in a clinical trial for treatment of patients post acute coronary syndrome . (PROVE IT)

Principal Investigator for AstraZeneca in a 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes. (LUNAR)

Prinicpal Investigator for Aventis open-label enoxaparin versus UFH in subjects who present to the emergency room with ACS (RESCUE)

 

CARDIAC INTERVENTIONAL STUDIES

Principal Investigator for Searle in the treatment of patients undergoing PTCA and/or stent procedures. (EXCITE)

 

ISCHEMIC/STABLE ANGINA

Principal Investigator for PACT in a clinical trial of Nicardipine for the treatment of stable angina pectoris.

Sub- Investigator for ICI in a clinical trial of Atenolol for treatment of silent ischemia. (ASSIST)

Principal Investigator for National Medical Research (now SCIREX) in the treatment of stable exertional angina comparing Amlodipine and Diltiazem.

Sub-Investigator for SmithKline and French Laboratories in (2) clinical trials of Carvedilol for treatment of stable angina.

Principal Investigator for National Medical Research in a clinical trial of Monoket vs. Procardia in the treatment of stable angina.

Principal Investigator for Marion Merrell Dow in a clinical trial of Cardizem CD in the treatment of stable angina pectoris.

Sub-Investigator for Ciba-Geigy in a clinical trial of Transderm-Nitro in the treatment of stable angina pectoris. (TIDES II)

Sub-Investigator for 3M Pharmaceuticals in a clinical trial of Minitran in the treatment of stable angina pectoris.

Sub-Investigator for Rhone-Poulenec Rorer in (2) clinical trials evaluating Dilacor in the treatment of stable angina.

Sub-Investigator for Zeneca Pharmaceuticals to evaluate exercise tolerance in patients treated for chronic stable angina

Principal Investigator for Hoechst-Roussel Pharmaceuticals in a clinical trial of Diltiazem in the treatment of chronic stable angina.

Sub-Investigator for Bristol-Myers Squibb in an ambulatory myocardial ischemia clinical trial.

Sub-Investigator for Bristol-Myers Squibb in a clinical trial of Ifetroban for treatment of chronic stable angina.

Sub-Investigator for Parke Davis in the treatment of patients with coronary artery disease, silent ischemia, and effort-induced angina. (QUASAR)

 

ARRHYTHMIAS

Sub-Investigator for Searle in a clinical trial of Bidisomide in the treatment of atrial fibrillation/flutter and paroxysmal supraventricular tachycardia.

Principal Investigator for Pfizer, Inc. in a clinical trial of intravenous Dofetilide for treatment of acute atrial fibrillation/flutter and paroxysmal supraventricular tachycardia.

Sub-Investigator for Proctor & Gamble in the treatment of symptomatic atrial fibrillation/flutter and PSVT. (SVA2)

Principal Investigator for Pfizer, Inc. in a clinical trial of Dofetilide for treatment of paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardia.

Sub-Investigator for Proctor & Gamble in the treatment of symptomatic atrial fibrillation/flutter and PSVT. (SVA3)

Sub-Investigator for SmithKline Beecham in a clinical trial for the treatment of atrial fibrillation and other supraventricular arrhythmias.

Sub-Investigator for Proctor & Gamble in the treatment of atrial fibrillation/flutter and PSVT. (SVA4)

Sub-Investigator for Knoll Pharmaceutical Company in the prevention of symptomatic recurrences of atrial fibrillation. (RAFT)

Sub-Investigator for Proctor and Gamble in a 12-month clinical trial to evaluate doses of oral Azilimide Dihydrochloride in patients with an ICD for the treatment of ventricular arrhythmia. (SHIELD)

Sub-Investigator for Proctor and Gamble, A Multi-Center, Open Label, Follow-Up Study to Assess the Long-Term Safety of 125 mg per day of Oral Azimilide Dihydrochloride in Patients with an ICD. (SHIELD OPEN LABEL)

Sub-Investigator for Proctor and Gamble to assess Azimilide Dihydrochloride for the treatment of atrial fibrillation in patients who require electrical cardioversion, with an open-label follow-up phase to assess the long-term efficacy and safety. (A-COMET I)

Sub-Investigator for Proctor and Gamble to assess Azimilide Dihydrochloride for prophylactic treatment of atrial fibrillation and an open-label follow-up to assess the long-term efficacy and safety. (A-STAR)

 

ANTI-COAGULANT

Sub-Investigator for Astra Zeneca in a clinical trial to compare an oral direct thrombin inhibitor to dose-adjusted Coumadin in patients with atrial fibrillation. (SPORTIF V)

 

ANTI-PLATELET AGGREGATION

Sub-Investigator for Bristol-Myers Squibb and Sanofi-Snythelabo, Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. (ACTIVE)

 

HYPERLIPIDEMIA

Principal Investigator for Sandoz Pharmaceuticals in a clinical trial of Lescol for hyperlipidemia.

Principal Investigator for a Merck Phase IV prospective observational study of Statins in high-risk patients.

Principal Investigator for Pfizer in an open-label 8-week treatment clinical trial evaluating Atorvastatin doses in dyslipidemic patients. (AT GOAL)

Sub-Investigator for AstraZeneca in a placebo-controlled, phase III, clinical trial in the prevention of cardiovascular events among subjects with low levels of LDL-C and elevated levels of C-Reactive Protein (JUPITER)

 

CLAUDICATION

Sub-Investigator for Bristol-Myers Squibb in a clinical trial of Ifetroban in the treatment of claudication.

Sub-Investigator for Otsuka Pharmaceuticals in a clinical trial to assess the long-term effects of Pletal versus placebo for patients with intermittent claudication secondary to peripheral arterial disease. (CASTLE)

 

HYPERTENSION

Principal Investigator for Merck Sharp & Dohme in a clinical trial of Plendil for treatment of uncomplicated essential hypertension.

Principal Investigator for Sankyo in a clinical trial of Temocapril in the treatment of hypertension.

Sub-Investigator for Takeda America in a clinical trial in the treatment of moderate hypertension.

Principal Investigator for Merck Pharmaceuticals in a clinical trial of Losartan vs. Amlodipine in the treatment of mild to moderate hypertension.

Sub-Investigator for Schwarz Pharmaceuticals in a clinical trial of Moexipril in mild-moderate hypertension with impaired renal function.

Principal Investigator for Bristol Myers Squibb in a clinical trial of Omapatrilat versus Enalapril in mild-moderate/severe hypertension. (OCTAVE)

 

 

 

 

Home | About Us | Office Locations | Procedures
Physicians | Prevention | Contact Us

 

 

The material provided on this site is for general information purposes only.
It is not intended to be used as medical advice and does not substitute
for proper consultation with trained medical personnel.